Equities research analysts expect Joint Corp (NASDAQ:JYNT) to report $11.80 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Joint’s earnings. The highest sales estimate is $12.20 million and the lowest is $11.48 million. Joint posted sales of $8.06 million in the same quarter last year, which suggests a positive year-over-year growth rate of 46.4%. The company is expected to report its next quarterly earnings results on Thursday, November 14th.
On average, analysts expect that Joint will report full-year sales of $46.44 million for the current year, with estimates ranging from $45.80 million to $47.30 million. For the next financial year, analysts anticipate that the company will post sales of $59.04 million, with estimates ranging from $58.05 million to $59.70 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover Joint.
Joint (NASDAQ:JYNT) last released its quarterly earnings results on Thursday, August 8th. The company reported $0.03 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.02 by $0.01. The business had revenue of $11.17 million during the quarter, compared to analyst estimates of $11.08 million. Joint had a net margin of 5.38% and a return on equity of 114.93%.
NASDAQ:JYNT traded up $0.79 during mid-day trading on Friday, hitting $19.17. The stock had a trading volume of 109,500 shares, compared to its average volume of 130,209. The stock has a market capitalization of $252.10 million, a price-to-earnings ratio of 479.25 and a beta of 1.02. The company has a 50 day simple moving average of $18.04 and a 200-day simple moving average of $17.78. Joint has a 52 week low of $6.51 and a 52 week high of $21.80. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 3.33.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Bandera Partners LLC grew its stake in shares of Joint by 4.6% in the 2nd quarter. Bandera Partners LLC now owns 1,364,301 shares of the company’s stock worth $24,830,000 after purchasing an additional 60,000 shares during the last quarter. BlackRock Inc. increased its position in shares of Joint by 1,224.0% in the second quarter. BlackRock Inc. now owns 769,378 shares of the company’s stock worth $14,002,000 after acquiring an additional 711,267 shares in the last quarter. Skylands Capital LLC increased its position in shares of Joint by 4.4% in the second quarter. Skylands Capital LLC now owns 550,701 shares of the company’s stock worth $10,023,000 after acquiring an additional 23,051 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Joint by 42.0% in the second quarter. Vanguard Group Inc. now owns 538,070 shares of the company’s stock worth $9,793,000 after acquiring an additional 159,034 shares in the last quarter. Finally, Acadian Asset Management LLC increased its position in shares of Joint by 17.3% in the second quarter. Acadian Asset Management LLC now owns 254,919 shares of the company’s stock worth $4,639,000 after acquiring an additional 37,653 shares in the last quarter. 62.76% of the stock is currently owned by institutional investors.
The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates through two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of March 07, 2019, the company operated 450 clinics in the United States.
Featured Story: The Role of a Fiduciary and Individual Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Joint Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Joint and related companies with MarketBeat.com's FREE daily email newsletter.